Abliva — Share Issue/Capital Change 2021

Apr 29, 2021

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) ("Abliva" or the "Company") has today held an Extraordinary General Meeting. Due to the continued spread of the coronavirus and the authorities' regulations/advice on avoiding public gatherings, the Extraordinary General Meeting was conducted only by postal vote and thus without physical presence of shareholders, proxies or external parties. A summary of the resolution follows.

Approval of resolution to issue shares with deviation from the shareholder's preferential rights

Today, the Extraordinary General Meeting approved the Board of Directors' resolution from 30 March 2021 to increase the company's share capital with no more than SEK 3,703,265.30 by a directed issue of not more than 74,065,306 shares (the "Shares"). The right to subscribe the new shares shall, for technical delivery reasons, belong to Erik Penser Bank AB (publ), for further delivery to several Swedish and international qualified investors. The price was determined by an accelerated bookbuilding procedure on 30 March 2021 to SEK 0.75 per share. The reason for the deviation from the shareholders' preferential rights is to be able to carry out a capital raise in a timely and cost-effective manner as well as to broaden the company's ownership. By reason of the Shares being admitted to trading, a prospectus is expected to be published on 30 April 2021.

In accordance with previously announced information on 30 March 2021, the Board of Directors revolved to issue a total of 106,666,666 shares to Swedish and international qualified investors through two tranches, of which 32,601,360 shares were issued based on the authorization from the Annual General Meeting on 20 May 2020, and 74,065,306 shares will be issued after approval of today's Extraordinary General Meeting. Abliva thus receives a total gross payment of SEK 80.0 million.

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations +46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) info@abliva.com, www.abliva.com

Subscribe to our news: https://abliva.com/posts/news-subscription/ Follow us on LinkedIn:https://www.linkedin.com/company/abliva Subscribe to our YouTube channel: https://www.youtube.com/channel /UChqP7Ky5caXtp72CELhD6Mg

Press Release Abliva AB (publ), 556595-6538

29 April 2021 12:40:00 CEST - Lund, Sweden

Abliva – Delivering mitochondrial health

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)